

NexPoint Capital BDC

The Company's Primary Offering Was Terminated On February 14, 2018.

NexPoint Capital, Inc. is a non-traded business development company (“BDC” or “the Company”) that seeks to provide investors access to the unique opportunities offered by the historic changes to our nation’s healthcare economy as a result of significant demographic and governmental changes.

Performance Review

The Company generated positive total return in the first quarter of 2021, with the NAV per share increasing to \$6.25 as of 3/31/21 vs \$6.13 as of 12/31/20. This performance was driven by steady returns from the portfolio’s healthcare positions, as well as improved performance from the portfolio’s real estate positions.

Market Outlook

Despite concerns around rising inflation and the subsequent spike in longer-dated yields, the S&P has continued through mini peaks and troughs to a 6.17% increase from the beginning of the year to the end of 1Q21. Overall, a focus on stronger economic growth, supportive Fed policy, and a rotation towards cyclicals supported the strength of the markets although this was more of a season of winners-and-losers rather than the broader uplift that underpinned 2020 equity performance. The US credit markets have seen more neutrality as momentum languished and inflation concerns hampered long duration despite the positive economic backdrop. Leveraged loans were the net beneficiaries in this environment and generated a 2.01% gain in 1Q21, given their floating rate structure, rising retail and institutional demand, and a likely upgrade cycle given continued fundamental improvement in 4Q20 results.

Healthcare equities (as reflected by the Healthcare Select Sector SPDR ETF, “XLV”) underperformed the S&P, although they still generated a 3.14% return in 1Q21, reflecting a net concern about the impact of forward drug pricing and other unfavorable potential healthcare regulation on primarily pharmaceutical and biotechnology companies which was offset by growing positive sentiment around normalization within traditional healthcare services and providers. The healthcare credit markets (as reflected by the JPM Healthcare

Fund Facts	
Net Asset Value Per Share	\$6.25
Quarterly Distribution Rate*	5.77%

Fund Characteristics	
Number of Investments	42
Loan Price (Wtd. Avg.)	\$89.8
Weighted Avg Credit Rating	Caa1

Credit Rating Breakdown	
B	52.6%
CCC	43.4%
NR	4.1%

Industry Breakdown	
Healthcare	63.2%
Real Estate	18.9%
Telemedia	8.5%
Other	3.9%
Consumer Products	3.2%
Financials	2.3%

Portfolio Allocation	
1st Lien Loans	49.8%
Equity	34.0%
Corporate Bonds	10.8%
2nd Lien Loans	4.8%
Asset Backed	0.6%

*Distributions are not guaranteed and may be suspended, modified or terminated at the discretion of the board of trustees. Distributions may be paid from offering proceeds and may include a return of capital or borrowed funds, which may lower overall returns to the investor and may not be sustainable. The Company had estimated returns of capital in 2020 of 100%.

NEXPOINT

Leveraged Loan Index) generated a 3.45% return in 1Q21 and outperformed the broader leveraged loan market, likely reflecting the higher composition of traditional healthcare services in the broader healthcare index, positive sentiment towards economic reopening, and 4Q20 earnings releases highlighting the sequential increase in utilization of services.

Looking forward, we have continued to position the portfolio for the more normalized utilization environment with the Covid-19 vaccine rollout while shying away from credits exposed to potential regulatory and legislative risk. Healthcare positions are weighted towards more outpatient facilities, services, and providers which have and should continue to benefit from an increase in previously deferred procedural volumes, secular tailwinds of lower-cost and outpatient care, and ample liquidity from federal grants and loans associated with the CARES Act. We have stayed away from pharmaceuticals and other subsectors exposed to bipartisan drug pricing reform and other potential adverse healthcare legislation. We carefully monitor and evaluate select higher yielding healthcare credits underpinned by strong fundamentals and substantiated growth outlooks as potential swap opportunities.

Top 5 Healthcare Holdings (As of 3/31/21)

Envision Healthcare	7.9%
BW NHHC Holdco	6.6%
RX Benefits	6.2%
Surgery Center	5.8%
Radnet Management	5.3%

Top Contributors

Position	Asset	Industry
NexPoint Real Estate Finance	Equity	Real Estate
SFR WLIF II, LLC	Equity	Real Estate
BW NHHC Holdco	1st Lien	Healthcare

Top Detractors

Position	Asset	Industry
Fieldwood	1st Lien	Energy
Fieldwood	2nd Lien	Energy
TerreStar Corporation	Equity	Telemedia

Disclosures

NexPoint Capital, Inc. concluded the company's public offering on February 14, 2018. For more information, please see the 8-K on the Fund website, www.nexpoint.com.

Investing in our shares of common stock may be considered speculative and involves a high degree of risk, including the risk of a substantial loss of investment. See the "Risk Factors" section of our prospectus to read about the risks you should consider before buying our shares including the risk of leverage.

The performance data quoted here represents past performance and is no guarantee of future results. Investment returns and principal value will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted. For performance data current to the most recent month-end, please call 833-697-7253.

RISK CONSIDERATIONS

Before investing in the Fund, you should carefully consider the Fund's investment objectives, risks, charges and expense. For a copy of a prospectus or summary prospectus, which contains this and other information, please visit our website at nexpoint.com or call 1-833-697-7253. Please read the fund prospectus carefully before investing.

- For the year ended December 31, 2016, 1.65% of the fund's total return consists of a voluntary reimbursement by the adviser for unrealized investment losses, and is included in Net realized and unrealized gain (loss). Excluding this item, total return would have been 25.96%. For the year ended December 31, 2015, 6.09% of the fund's total return consists of a voluntary reimbursement by the Adviser for unrealized investment losses, and is included in Net realized and unrealized gain (loss). Excluding this item, total return would have been (9.35)%.
- Total returns are historical and assume changes in share price and reinvestment of dividends and capital gains distributions, and assume no sales charge. Distributions, if any, are assumed for purposes of this calculation to be reinvested at prices obtained under the Company's Dividend Reinvestment Plan. Had the Adviser not absorbed a portion of expenses, total returns would have been lower.
- On June 13, 2017, the Company entered into the TRS with BNP Paribas over one or more loans, with a maximum aggregate notional amount of the portfolio debt securities subject to the TRS of \$40 million. The agreements between the Company and BNP Paribas, which collectively establish the TRS, are referred to herein as the "TRS Agreement." 31 On April 2, 2018, the Company amended and restated the TRS agreement with BNP Paribas. The amended and restated TRS Agreement, effective April 10, 2018 increases the maximum aggregate notional amount of the portfolio debt securities subject to the TRS to \$60 million. A TRS is a contract in which one party agrees to make payments to another party based on the increase, if any, in the market value of the asset(s) underlying the TRS, which may include a specified security, basket of securities or securities indices during a specified period, and the other party agrees to make payments to the first party based on the decrease, if any, in the market value of such underlying assets plus periodic payments based on a fixed or variable interest rate. A TRS effectively adds leverage to a portfolio by providing investment exposure to an underlying asset without owning or taking physical custody of the underlying asset. A TRS often offers lower financing costs than are offered through more traditional borrowing arrangements.
- Distributions are not guaranteed and may be suspended, modified or terminated at the discretion of the board of directors. Distributions may include a return of principal or borrowed funds, which may lower overall returns to the investor and may not be sustainable.
- The Expense Limitation Agreement is contractual and will continue through at least April 30, 2021.
- You should not expect to be able to sell your shares of common stock regardless of how we perform.
- If you are able to sell your shares of common stock, you will likely receive less than your purchase price.
- We do not intend to list our shares of common stock on any securities exchange during, or for what may be a significant time after, the offering period, and we do not expect a secondary market in the shares of common stock to develop.
- Because our common stock will not be listed on a securities exchange, you may be unable to sell your shares and, as a result, you may be unable to reduce your exposure on any market downturn.
- We intend to implement a share repurchase program, but we do not expect to repurchase more than 10% of the weighted average number of shares that were outstanding in the prior calendar year. In addition, any such repurchases will be at a 10% discount to the current offering price in effect on the date of repurchase.
- Our distributions may be funded from offering proceeds or borrowings, which may constitute a return of capital and reduce the amount of capital available to us for investment. Any capital returned to stockholders through distributions will be distributed after payment of sales load, fees and expenses and such amounts will not be recoverable by our stockholders.
- You should consider that you may not have access to the money you invest for an indefinite period of time. An investment in our shares of common stock is not suitable for you if you need access to the money you invest. See "Share Repurchase Program," "Suitability Standards" and "Liquidity Strategy."
- The lack of experience of our investment adviser operating under the constraints imposed on us as a business development company and RIC may hinder the achievement of our investment objective.
- We intend to finance our investments with borrowed money, which will magnify the potential for gain or loss on amounts invested and may increase the risk of investing in us.
- We are subject to risks associated with middle-market healthcare companies, including competition, extensive government regulation and commercial difficulties.
- Our CLO investments may be riskier and less transparent to us and our stockholders than direct investments in the underlying companies. Our investments in equity and mezzanine tranches of CLOs will likely be subordinate to the other debt tranches of such

CLOs, and are subject to a higher degree of risk of total loss.

- There are significant potential conflicts of interest that could affect our investment returns.

Index Definitions:

Index returns assume reinvestment of all dividends and distributions, if any. Indices are unmanaged, have no fees or costs and are not available for investment. The performance of the indices may be materially different from the Fund's performance. In addition, the Fund's holdings may differ significantly from the securities that comprise the indices. The indices have not been selected to represent an appropriate benchmark to compare a fund's performance, but rather are disclosed to allow for comparison of the Fund's performance to that of certain well-known and widely recognized indices. It is not possible to invest directly in an index. **S&P 500 Index.** S&P 500 Index is an index of a basket of 500 stocks designed to provide a broad snapshot of the overall U.S. equity market. Criteria for inclusion: U.S. Company, market capitalization must be in excess of US\$ 3 billion, public float of at least 50%, financial viability, adequate liquidity and reasonable price, sector balance, and company type. Ordinary cash dividends are applied on the ex-date in calculating the total return series. "Special dividends" are those dividends that are outside of the normal payment pattern established historically by the issuing corporation. The total return index series reflect both ordinary and special dividends. **JPM Leveraged Loan Index/Healthcare Index.** This index is designed to mirror the investable universe of U.S. dollar institutional leveraged loans, including U.S. and international borrowers. The J.P. Morgan U.S. Liquid Index is a market-weighted index that measures the performance of the most liquid issues in the investment grade, dollar-denominated corporate bond market. **Healthcare Select Sector SPDR ETF ("XLV").** The Health Care Select Sector SPDR Fund seeks to provide investment results that, before expenses, correspond generally to the price and yield performance of publicly traded equity securities of companies in the Health Care Select Sector Index (the "Index"). The Index is also sponsored and compiled by S&P DJI. The Index includes companies from the following industries: pharmaceuticals; health care equipment and supplies; health care providers and services; biotechnology; life sciences tools and services; and health care technology.

Sources: SEI, Bloomberg

Prepared by NexPoint Securities, Inc., Member FINRA/SIPC. NexPoint Securities is the dealer manager for the NexPoint Capital, Inc. offering.

NOT FDIC INSURED. MAY LOSE VALUE. NO BANK GUARANTEE.

NEXPOINT

www.nexpoint.com

833.697.7253